
    
      This study will be an open label, long term extension study in subjects with atherosclerotic
      cardiovascular disease (ASCVD), ASCVD-risk equivalents (eg, diabetes and familial
      hypercholesterolemia), or heterozygous or homozygous familial hypercholesterolemia (HeFH or
      HoFH) and elevated low density lipoprotein cholesterol (LDL-C) despite maximum tolerated dose
      of LDL-C lowering therapies who have completed any of the following inclisiran Phase III
      lipid lowering studies: MDCO-PCS-17-03 (ORION-9), MDCO-PCS-17-04 (ORION-10), MDCO-PCS-17-08
      (ORION-11) or MDCO-PCS-17-02 (ORION-5).
    
  